07:00 , May 18, 2015 |  BioCentury  |  Strategy

Alexion executes

The proposed acquisition of Synageva BioPharma Corp. is Alexion Pharmaceuticals Inc.'s biggest move to date under a four-year-old plan to diversify its portfolio. The plan, announced in 2011, includes expanding Soliris eculizumab beyond paroxysmal nocturnal...